STOCK TITAN

Anixa Biosciences, Inc. - ANIX STOCK NEWS

Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.

The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.

Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that its collaborator, Cleveland Clinic, has received a 'Decision to Grant' notice from the Japan Patent Office for a patent application on breast cancer vaccine technology. This extends the patent protection to Japan, in addition to existing U.S. and European patents. Anixa is the exclusive worldwide licensee of this technology.

The vaccine, currently in phase one clinical trials at Cleveland Clinic, targets α-lactalbumin, a breast-specific lactation protein present in certain breast cancers but not in normal aging tissues post-lactation. By activating the immune system against this 'retired' protein, the vaccine aims to provide preemptive protection against emerging breast tumors expressing α-lactalbumin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company focused on cancer treatment and prevention, has announced a $5 million share repurchase program. The program, authorized by the Board of Directors, allows for the repurchase of outstanding common stock over a 12-month period. Dr. Amit Kumar, Chairman and CEO, stated that this decision reflects confidence in the company's future outlook, balance sheet strength, and clinical development pipeline. He also expressed the belief that Anixa's stock is currently undervalued.

The repurchases will be made through open-market transactions in compliance with securities laws. The program can be suspended or discontinued at any time, and no shares have been repurchased to date. This initiative aims to enhance long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.25%
Tags
buybacks
-
Rhea-AI Summary

Anixa Biosciences has treated the sixth and final patient in the second dosage cohort of its Phase 1 clinical trial for an ovarian cancer CAR-T therapy, partnered with Moffitt Cancer Center. If no adverse effects are observed, the third dosage cohort, with a tenfold increase in dose, may commence next month. The trial focuses on evaluating the safety and efficacy of Anixa's FSHR-targeting CAR-T technology. The first cohort showed no dose-limiting toxicities, and a notable response from one patient was observed despite the subtherapeutic dose. The second cohort, receiving triple the initial dose, also reported no dose-limiting toxicities. The therapy involves intraperitoneal delivery, which potentially minimizes side effects and enhances targeting efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary

Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), which is uniquely expressed on ovarian cells. Safety was confirmed in the first cohort of three patients, and the second cohort, including the fifth patient, receives triple the dose of engineered T-cells. According to Dr. Amit Kumar, Anixa's Chairman and CEO, the trial continues to show that the therapy is safe and well-tolerated, offering hope for an effective CAR-T treatment for solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
-
Rhea-AI Summary

Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
partnership
-
Rhea-AI Summary

Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
Rhea-AI Summary

Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
conferences
-
Rhea-AI Summary
Anixa Biosciences, a clinical-stage biotechnology company, appoints Dr. Sanjay Juneja, a renowned oncologist, to its Cancer Business Advisory Board. Dr. Juneja's expertise and influence in cancer prevention and treatment will benefit Anixa's mission in advancing cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
management
-
Rhea-AI Summary
Anixa Biosciences, Inc. announces its 2024 Annual Meeting of Stockholders to discuss its portfolio of oncology/immunology assets, including vaccines to prevent cancer and CAR-T cell therapy to treat cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
Rhea-AI Summary
Anixa Biosciences, Inc. announces CEO's participation in the 24th Annual World Vaccine Congress to discuss early-stage clinical results on a preventative breast cancer vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none

FAQ

What does Anixa Biosciences specialize in?

Anixa Biosciences specializes in developing vaccines and therapies aimed at the treatment and prevention of cancer, focusing on critical unmet needs in oncology.

What are the key components of Anixa's therapeutic portfolio?

Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program using CER-T technology and vaccine programs focused on preventing breast and ovarian cancers.

What recent achievements has Anixa Biosciences announced?

Recent achievements include receiving an 'Intention to Grant' notice from the European Patent Office for their ovarian cancer vaccine and presenting positive Phase 1 trial results for their breast cancer vaccine.

Who are some of Anixa Biosciences' key collaborators?

Key collaborators include Moffitt Cancer Center for immunotherapy programs and Cleveland Clinic for vaccine development.

How does Anixa's CER-T technology differ from traditional CAR-T therapies?

Anixa's CER-T technology targets the follicle-stimulating hormone receptor (FSHR), which is specifically expressed on ovarian cells, offering a novel approach to treating solid tumors, unlike traditional CAR-T therapies.

What is unique about Anixa's cancer vaccine technology?

Anixa's cancer vaccine technology is unique in that it targets 'retired' proteins found to be expressed in specific forms of cancer, providing preemptive immune protection against emerging tumors.

Which forms of cancer are Anixa's vaccines targeting?

Anixa's vaccines are currently targeting triple-negative breast cancer (TNBC), the most lethal form of breast cancer, and ovarian cancer.

What are some recent clinical trial results from Anixa?

Recent clinical trial results include positive Phase 1 trial data for their breast cancer vaccine, showing antigen-specific T cell responses and an increase in immune-mediated biomarkers.

Does Anixa Biosciences participate in industry conferences?

Yes, Anixa actively participates in industry conferences such as the 2024 NeauxCancer Conference and the World Vaccine Congress to present their latest developments and foster collaborations.

Where can I find more information about Anixa Biosciences?

More information about Anixa Biosciences can be found on their website at www.anixa.com or by following them on social media platforms like Twitter, LinkedIn, Facebook, and YouTube.

Anixa Biosciences, Inc.

Nasdaq:ANIX

ANIX Rankings

ANIX Stock Data

94.10M
32.01M
5.05%
16.46%
1.77%
Computer Storage Device Manufacturing
Manufacturing
Link
United States of America
SAN JOSE